ITEMS IN AFP WITH KEYWORD:
Dapagliflozin can be added to existing treatment to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes who have established CVD or are at high risk of CVD. It may also decrease the risk of renal disease progression and death from renal failure.
Feb 15, 2020 Issue
Diagnosis of Heart Failure with Reduced Ejection Fraction [Point-of-Care Guides]
Can signs, symptoms, and simple tests be used to determine the likelihood of heart failure with reduced ejection fraction?
Jul 1, 2019 Issue
Medication Management for Chronic Heart Failure with Preserved Ejection Fraction [Cochrane for Clinicians]
Mineralocorticoid receptor antagonists reduce hospitalizations for patients with HFpEF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have not been shown to change the morbidity or mortality in patients with HFpEF.
Compared with monotherapy, the combination of an ACE inhibitor and an ARB has not been shown to improve cardiovascular or overall mortality in patients with symptomatic heart failure. The combination is associated with an increased number of adverse drug effects.
A simple clinical prediction rule using noninvasive data can identify patients at low, moderate, and high risk for HFPEF.
This review concluded that the individual components of the clinical history and physical examination, electrocardiography, and chest radiography are not useful independently for confirming or excluding the diagnosis of acute heart failure syndrome in patients presenting to the emergency department.
Changes in how cardiomyopathy is understood have been considerable in recent years. Although diagnosis and treatment guidelines regularly align, controversy remains regarding when to apply restrictions on sports participation. Of the many disease forms discussed in this article, hypertrophic cardiomyopathy is the most likely to be seen in primary care practice.
About one-half of the 5 million Americans diagnosed with heart failure have preserved ejection fraction. Find out which signs and symptoms increase the likelihood of heart failure, and get the latest evidence on which medications should be used to treat these patients.
Aug 1, 2017 Issue
Antiplatelet vs. Anticoagulation Therapy for Patients with Heart Failure in Sinus Rhythm [Cochrane for Clinicians]
Heart failure increases the risk of thrombotic complications, but use of warfarin does not lower all-cause mortality more than aspirin in patients with heart failure with reduced ejection fraction in sinus rhythm.